PDS Biotechnology Corporation (NASDAQ:PDSB) Sees Large Drop in Short Interest

Share on StockTwits

PDS Biotechnology Corporation (NASDAQ:PDSB) saw a significant decline in short interest during the month of November. As of November 29th, there was short interest totalling 33,300 shares, a decline of 33.4% from the November 14th total of 50,000 shares. Based on an average trading volume of 90,800 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.2% of the company’s stock are sold short.

A number of brokerages recently issued reports on PDSB. Chardan Capital started coverage on shares of PDS Biotechnology in a research report on Wednesday, October 23rd. They set a “buy” rating and a $10.00 price objective for the company. HC Wainwright started coverage on shares of PDS Biotechnology in a research report on Tuesday, November 5th. They set a “buy” rating and a $7.00 price objective for the company.

Shares of PDS Biotechnology stock traded down $0.02 during trading on Thursday, reaching $2.72. The company’s stock had a trading volume of 11,317 shares, compared to its average volume of 73,424. The stock has a 50-day moving average price of $2.71. The company has a market capitalization of $16.64 million, a price-to-earnings ratio of -0.15 and a beta of 2.26. PDS Biotechnology has a fifty-two week low of $2.02 and a fifty-two week high of $11.80.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.28). On average, equities research analysts forecast that PDS Biotechnology will post -1.38 EPS for the current fiscal year.

An institutional investor recently bought a new position in PDS Biotechnology stock. Amussen Hunsaker Associates LLC acquired a new position in PDS Biotechnology Corporation (NASDAQ:PDSB) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 14,641 shares of the company’s stock, valued at approximately $49,000. Amussen Hunsaker Associates LLC owned approximately 0.25% of PDS Biotechnology as of its most recent SEC filing. Hedge funds and other institutional investors own 8.83% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

Featured Article: Liquidity

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
PNM Resources Inc  Shares Sold by James Investment Research Inc.
PNM Resources Inc Shares Sold by James Investment Research Inc.
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc


© 2006-2020 Ticker Report